Ultragenyx to sell FDA-awarded PRV for $210M cash; 20% of proceeds owed to NIH

Ultragenyx Pharmaceutical Inc.

Asset purchase agreement signed Oct 6, 2026 to sell the Rare Pediatric Disease Priority Review Voucher awarded by FDA on Aug 19, 2026.
$210 million payable in cash to Ultragenyx at closing; no buyer named in the filing.
20% of gross proceeds (~$42M) payable to the NIH under a patent license agreement dated Dec 10, 2018.
PRV stemmed from FDA approval of GENGLYCOS (pariglasgene brecaparvovec-opnr), or DTX401, for glycogen storage disease type Ia in patients 8 and older.
Closing subject to customary conditions, including expiry or termination of the HSR waiting period; agreement to be filed with the FY2026 10-K.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.